Diabetes

An experimental drug that inhibits aldosterone production reduced albuminuria in patients with chronic kidney disease, according to phase 2 study results published in The Lancet.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM, about situations in which an ultra-long-acting insulin may be a good choice.

Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new data on how a class of drugs used in type 2 diabetes may also be beneficial in patients with lupus and gout.

Survivors of childhood cancer are more likely to have prediabetes at younger ages than the general public, increasing their already elevated risk for diabetes and cardiovascular and kidney diseases, study findings showed.

Inflammasome Therapeutics announced that the first patient has been dosed in its phase 1 study of K8, a novel dual inflammasome inhibitor for treatment of diabetic macular edema.

New data from the American Heart Association show the overall number of CV-related deaths again rose year over year from 2020 to 2021, though the increase was far smaller than what was observed the previous year.

Gabapentinoid use has continued to increase in the last several years despite a “dearth of evidence” that supports the drug’s use, according to researchers.

Health Canada has approved the use of Jardiance for the treatment of adults with chronic kidney disease, according to a press release.

Monitoring nutritional status is not the same for pediatric and adult patients with chronic kidney disease, and all nephrologists should be aware of the differences, according to an article in Seminars in Nephrology.

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.